SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
members of its leadership team will be making presentations at
several high-profile events in February, including:
- The 18th Annual BIO CEO & Investor Conference
- Source Capital Group's 2016 Disruptive Growth & Healthcare
Conference
- Biocom's Global Life Science Partnering Conference
- 4th Annual Sachs Cancer Bio Partnering & Investment
Forum
The 18th Annual BIO CEO & Investor Conference
Punit Dhillon, President and CEO,
will present a corporate overview at The 18th Annual BIO CEO &
Investor Conference on February 8 at
11:00 AM ET at The Waldorf Astoria in
New York City. To view to the live
webcast, please access the following link at the time of the
presentation:
http://www.veracast.com/webcasts/bio/ceoinvestor2016/76113125724.cfm.
An archived version of the webcast will be available for 90 days on
OncoSec's website: http://www.oncosec.com.
In its eighteenth year, The BIO CEO & Investor Conference is
the largest investor conference focused on established and emerging
publicly traded and select private biotech companies. Companies are
able to present their company story to an audience of target
investors and meet one-on-one with new and current investors,
analysts, investment bankers, and other potential corporate
partners. The conference also provides a platform to network with
peers, investors, and potential partners attending the conference.
For more information, please visit:
https://www.bio.org/events/conferences/bio-ceo-investor-conference.
Source Capital Group's 2016 Disruptive Growth &
Healthcare Conference
Mr. Dhillon will present a corporate
overview at Source Capital Group's 2016 Disruptive Growth &
Healthcare Conference on February 10
at 12:30 PM ET at Convene in
New York City.
The 2016 Disruptive Growth & Healthcare Conference will
feature presentations from life science companies focusing on
solutions to unmet medical needs and growth companies with
disruptive technologies and business models. Attendees will include
over 400 institutional investors, accredited investors, family
offices, analysts, registered investment advisors, wealth managers,
Source representatives, and their clients. The panels will cover a
variety of topics, including regenerative medicine, immunotherapy,
diagnostics, disruptive innovations, and business models. For more
information, please visit: www.sourcecapitalconference.com.
Biocom's Global Life Science Partnering Conference
Mr. Dhillon will present a corporate overview at Biocom's Global
Life Science Partnering Conference taking place February 24-25 at The Lodge at Torrey Pines in La
Jolla, CA.
Biocom's 6th Annual Global Life Science Partnering Conference is
an exclusive global partnering and networking forum that brings
together senior executives, bankers, venture capitalists, and
business development professionals from leading pharmaceutical and
biotech companies. The conference will include panel discussions on
relevant topics with senior industry leaders, start-up company
presentations, one-on-one meetings, and numerous networking
opportunities. For more information, please visit:
https://www.biocom.org.
4th Annual Sachs Cancer Bio Partnering & Investment
Forum
Robert H. Pierce, MD,
Chief Scientific Officer, will present a corporate overview at the
4th Annual Sachs Cancer Bio Partnering & Investment Forum on
February 24 at 2:40 PM ET at the New York Academy of Sciences in
New York City.
The 4th Annual Sachs Cancer Bio Partnering & Investment
Forum is designed to bring together thought leaders from cancer
research institutes, patient advocacy groups, pharmaceutical, and
biotech to facilitate partnering and funding/investment. The
conference will attract approximately 250 delegates and 30 company
presentations by listed and private biotechnology companies seeking
licensing and investment opportunities. The event provides a
platform for one-on-one meetings and dedicated meeting facilities
to make the event more productive. For more information, please
visit: http://www.sachsforum.com/.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-prominent-investment-conferences-in-february-300214342.html
SOURCE OncoSec Medical Incorporated